Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale
01/12/2026 01:33 PM • Alnylam Pharmaceuticals announced its 'Alnylam 2030' five-year roadmap, targeting durable global leadership in transthyretin (TTR) diseases with plans to launch nucresiran by 2028-2030. The company projects 2026 net product revenue of $4.9-5.3 billion (71% growth), significantly above Street estimates, with TTR franchise expected to reach $4.4-4.7 billion. However, shares fell 10% on Monday despite strong guidance, as 2025 revenues narrowly missed expectations.
ALNY - Positive strategic outlook with ambitious 2030 goals and strong 2026 revenue guidance significantly above Street estimates ($4.9-5.3B vs. lower expectations). However, negative price action (-10%) reflects disappointment that 2025 revenues narrowly missed estimates, suggesting market concerns about execution despite bullish forward guidance.
Investing.com • Sam Quirke